Effects of Dietary Fructose on Gut Microbiota and Fecal Metabolites in Obese Men and Postmenopausal Women: A Pilot Study
الكلمات الدالة
نبذة مختصرة
وصف
Non- alcoholic fatty liver disease (NAFLD) occurs in 30% of the adult US population (Luther, J., et al., 2015). Eating large amounts of fructose (a dietary sugar) increases liver fat accumulation and worsens NAFLD. In addition, fructose consumption has been shown to greatly increase triglycerides(fat) in the blood after meals, increasing the risk of heart disease,(Stanhope,et al., 2009) insulin resistance and diabetes. Current theories on liver disease caused by consuming fructose focuses on changes in the breakdown of fat by the liver. In experimental animals, fructose feeding changes the bacteria population (microbiota) in the gut, causes NAFLD and NASH, and increases leaking of toxins from the intestine (intestinal permeability) to the blood stream resulting in inflammation.
In humans, fructose consumption rapidly increases liver fat. However, changes in gut microbiota have not been studied. The proposed study will compare the addition of fructose or glucose to the study subjects' usual diet in a crossover design. They will not know which sugar they are receiving.
The Investigators plan to study postmenopausal, moderately obese but healthy women, and moderately obese but healthy men (age 45-70 years) to find out the effect of fructose verses glucose on the bacteria in their stool and inflammation in the bowel. The Investigators hypothesize that adding fructose to the participant's usual diet, compared to glucose, will change stool bacteria composition and the products that the bacteria produce, which may increase intestinal leakage, and increase markers of inflammation in the stool and blood due to this leakage. These changes may contribute to fructose -induced liver disease.
تواريخ
| آخر التحقق: | 01/31/2019 |
| تم الإرسال لأول مرة: | 11/06/2017 |
| تم إرسال التسجيل المقدر: | 11/06/2017 |
| أول نشر: | 11/12/2017 |
| تم إرسال آخر تحديث: | 02/03/2019 |
| آخر تحديث تم نشره: | 02/04/2019 |
| تاريخ بدء الدراسة الفعلي: | 12/04/2017 |
| تاريخ الإنجاز الأساسي المقدر: | 10/01/2018 |
| التاريخ المتوقع لانتهاء الدراسة: | 10/01/2018 |
حالة أو مرض
التدخل / العلاج
Other: Fructose Solution (75 Grams)
Other: Glucose Solution (75 grams)
مرحلة
مجموعات الذراع
| ذراع | التدخل / العلاج |
|---|---|
| Experimental: Glucose, Then Fructose Participants first receive Glucose Solution (75 grams) from Day 3 through Day 16 of an inpatient stay with usual diet. After a 2-3 week washout period, they will then receive Fructose Solution (75 Grams) from Day 3 through Day 16 on a second inpatient stay with usual diet. | |
| Experimental: Fructose, Then Glucose Participants first receive Fructose Solution (75 grams) from Day 3 through Day 16 of an inpatient stay with usual diet. After a 2-3 week washout period, they will then receive Glucose Solution (75 grams) from Day 3 through Day 16 on a second inpatient stay with usual diet. |
معايير الأهلية
| الأعمار المؤهلة للدراسة | 45 Years إلى 45 Years |
| الأجناس المؤهلة للدراسة | All |
| يقبل المتطوعين الأصحاء | نعم |
| المعايير | Inclusion Criteria: - Post menopausal female, last menstrual period at least 24 months ago OR male - Age 45-70 - Willing to consume usual diet with either fructose or glucose added during (2) 16-18 day inpatient stays - Willing to consume usual diet during 2 week wash-out period at home - BMI 30.0-39.9 - Willingness not to travel long distances while on study, including wash-out period - Willingness not to be exposed to new pets while on study including wash-out period Exclusion Criteria: - Fasting serum triglycerides >200mg/dl - Fasting blood glucose >126mg/dl - Renal function tests >2x Upper limit of normal - Liver Function Tests > 1.5x Upper limit of normal - Currently on statins - Daily use of a cathartic - Broad spectrum antibiotic use within the past 45 days - Currently on proton pump inhibitor - Currently on insulin or oral hypoglycemic agents - Active viral Hepatitis - Chronic constipation - Inflammatory bowel disease - Chronic diarrhea - GI resection - Any evidence of cardiovascular disease on EKG - History of cardiovascular disease such as coronary artery disease, Coronary Artery Bypass Graft, valve replacement, Myocardial Infarction, stroke / Transient Ischemic attack. - History of macronutrient malabsorption - Current smoker. Stopped < 3 months ago. - Daily alcohol intake equal to 1.5 oz of 40 proof alcohol. - HIV positive - Any medical, psychological or social condition that, in the opinion of the Investigator, would jeopardize the health or well-being of the participant during any study procedures or the integrity of the data - Persons taking probiotics |
النتيجة
مقاييس النتائج الأولية
1. Difference in the distribution of fecal microbiota in each participant [assessed at Day 16 of each intervention, up to 64 days]
